Career development activities were a major focus of the initial funding period of the Kidney Cancer SPORE. Many investigators within the DF/HCC Kidney Cancer SPORE have had a longstanding interest and substantial track record in mentoring of junior faculty with an interest in cancer research. The funding of the Kidney Cancer SPORE in 2003 enabled us to establish a formal process for the identification, selection, funding and mentoring of young investigators seeking to pursue careers in basic and clinical aspects of kidney cancer research. In addition, as this field has traditionally received only modest interest from young investigators, it enabled us to focus on marketing to young investigators the potential benefits of pursuing a research career focused on kidney cancer. We feel that our efforts to date have been an unqualified success, with no fewer than 15 young investigators establishing independent academic careers focused at least partially on kidney cancer as a consequence of their interactions with the SPORE. Several of these individuals are leading Kidney Cancer Programs at major academic institutions creating opportunities to multiply the impact of the SPORE on the field (see below and in the Career Development Program Progress Report). We have also been successful at obtaining institutional and outside support for the Career Development Program, which has added to our ability to support young faculty pursuing careers in kidney cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA101942-10
Application #
8517024
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
10
Fiscal Year
2013
Total Cost
$68,398
Indirect Cost
$15,410
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Chen, Fengju; Zhang, Yiqun; ÅženbabaoÄŸlu, Yasin et al. (2016) Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep 14:2476-89
Choueiri, Toni K; Fishman, Mayer N; Escudier, Bernard et al. (2016) Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res :
Albiges, Laurence; Hakimi, A Ari; Xie, Wanling et al. (2016) Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Clin Oncol :
Schildberg, Frank A; Klein, Sarah R; Freeman, Gordon J et al. (2016) Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity 44:955-72
de Velasco, Guillermo; Miao, Diana; Voss, Martin H et al. (2016) Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. Cancer Immunol Res 4:820-822
de Velasco, Guillermo; Krajewski, Katherine M; Albiges, Laurence et al. (2016) Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Cancer Immunol Res 4:12-7
Gelpi-Hammerschmidt, Francisco; Tinay, Ilker; Allard, Christopher B et al. (2016) The Contemporary Incidence and Sequelae of Rhabdomyolysis Following Extirpative Renal Surgery: A Population Based Analysis. J Urol 195:399-405
Robson, Philip M; Madhuranthakam, Ananth J; Smith, Martin P et al. (2016) Volumetric Arterial Spin-labeled Perfusion Imaging of the Kidneys with a Three-dimensional Fast Spin Echo Acquisition. Acad Radiol 23:144-54
Meng, Chen; Zeleznik, Oana A; Thallinger, Gerhard G et al. (2016) Dimension reduction techniques for the integrative analysis of multi-omics data. Brief Bioinform 17:628-41
Reardon, David A; Gokhale, Prafulla C; Klein, Sarah R et al. (2016) Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res 4:124-35

Showing the most recent 10 out of 118 publications